Provided by Tiger Trade Technology Pte. Ltd.

AKESO

95.350
-5.850-5.78%
Volume:21.57M
Turnover:2.04B
Market Cap:87.82B
PE:-66.41
High:97.950
Open:95.000
Low:91.900
Close:101.200
52wk High:159.800
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:1.60
T/O Rate:2.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.436
ROE:-13.59%
ROA:-4.57%
PB:8.89
PE(LYR):-66.41
PS:21.85

Loading ...

Akeso - Study Meets Key Secondary Endpoints of Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Aug 26

Movement Alert|AKESO Rises 3.49% in Regular Trading, Interim Results Imminent and New ADC Pipeline Progress Boosts Sentiment

Market Focus
·
Aug 24

Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors

Reuters
·
Aug 21

Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

THOMSON REUTERS
·
Aug 21

Movement Alert|AKESO Declines 3.41% in Regular Trading, Profit-Taking Resumes After Prior Sessions Sharp Rebound

Market Focus
·
Aug 21

Earning Preview: AKESO revenue is expected to increase, institutional views lean positive

Earnings Agent
·
Aug 20

Movement Alert|AKESO Rises 6.49% in Regular Trading, Earnings Preview and Technical Rebound After Overselling Drive Recovery

Market Focus
·
Aug 20

Akeso (SEHK:9926) Could Be 47% Undervalued As China Approves Ivonescimab Use

Simply Wall St.
·
Aug 19

Movement Alert|AKESO Falls 3.09% in Regular Trading, Profit-Taking Continues After Third Indication Approval

Market Focus
·
Aug 18

Movement Alert|AKESO Falls 3.49% in Regular Trading, Profit-Taking Continues After Third Indication Approval for Ivonescimab

Market Focus
·
Aug 17

What Does Akeso (SEHK:9926) China Lung Cancer Approval Mean For Investors?

Simply Wall St.
·
Aug 14

Movement Alert|AKESO Falls 3.19% in Regular Trading, Biotech Sector Broadly Under Pressure After Third Indication Approval

Market Focus
·
Aug 14

Akeso's Ivonescimab Gets Third Indication Approval in China

MT Newswires Live
·
Aug 13

Movement Alert|AKESO Rises 3.04% in Regular Trading, Third Indication of Bispecific Antibody Ivonescimab Approved by NMPA

Market Focus
·
Aug 13

Akeso Says NMPA Approves Ivonescimab for 1L Treatment of SQ-NSCLC

Reuters
·
Aug 13

Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo

Reuters
·
Aug 12

AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC

Stock News
·
Aug 12

Akeso - Nmpa Approves Ivonescimab for 1L Treatment of Sq-Nsclc

THOMSON REUTERS
·
Aug 12

Akeso Says China NMPA Approves Ivonescimab Plus Chemo for First-Line Squamous NSCLC

Reuters
·
Aug 12

Akeso - China Nmpa Approves Ivonescimab Plus Chemotherapy for First-Line Advanced Squamous Nsclc

THOMSON REUTERS
·
Aug 12